CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Eblen, S. T.
Right arrow Articles by Leof, E. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Eblen, S. T.
Right arrow Articles by Leof, E. B.

Cell Growth & Differentiation, Vol 5, Issue 2 109-116, Copyright © 1994 by American Association of Cancer Research

ARTICLES

Cell cycle-dependent inhibition of p34cdc2 synthesis by transforming growth factor beta 1 in cycling epithelial cells

ST Eblen, MP Fautsch, RJ Burnette, P Joshi and EB Leof
Department of Cell Biology, Vanderbilt University, Nashville, Tennessee 37232.

Cycling epithelial cells were shown to reversibly arrest in late G1 phase following treatment with transforming growth factor beta 1. Associated with this G1-S phase arrest was a decrease in the synthesis and histone H1 kinase activity of p34cdc2. Transforming growth factor beta 1 did not reduce p34cdc2 levels by modulating the turnover of newly synthesized p34cdc2. The decrease in p34cdc2 synthesis preceded any detectable effect on DNA synthesis. Moreover, the action of transforming growth factor beta 1 was regulated in a cell cycle-specific manner; epithelial cells were sensitive to transforming growth factor beta 1 only during the G1 phase. The results suggest that p34cdc2 might be a useful biochemical marker for investigating the mechanism(s) of transforming growth factor beta 1 signaling.


This article has been cited by other articles:


Home page
 Mol. Pharmacol.Home page
G. Elizondo, P. Fernandez-Salguero, M. S. Sheikh, G.-Y. Kim, A. J. Fornace, K. S. Lee, and F. J. Gonzalez
Altered Cell Cycle Control at the G2/M Phases in Aryl Hydrocarbon Receptor-Null Embryo Fibroblast
Mol. Pharmacol., May 1, 2000; 57(5): 1056 - 1063.
[Abstract] [Full Text]

Home page
 J. Biol. Chem.Home page
K. S. Choi, Y. W. Eom, Y. Kang, M. J. Ha, H. Rhee, J.-W. Yoon, and S.-J. Kim
Cdc2 and Cdk2 Kinase Activated by Transforming Growth Factor-beta 1 Trigger Apoptosis through the Phosphorylation of Retinoblastoma Protein in FaO Hepatoma Cells
J. Biol. Chem., November 5, 1999; 274(45): 31775 - 31783.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. T. Hartsough, R. S. Frey, P. A. Zipfel, A. Buard, S. J. Cook, F. McCormick, and K. M. Mulder
Altered Transforming Growth Factor beta Signaling in Epithelial Cells when Ras Activation Is Blocked
J. Biol. Chem., September 13, 1996; 271(37): 22368 - 22375.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
X.-H. Feng, E. H. Filvaroff, and R. Derynck
Transforming Growth Factor-beta (TGF-beta)-induced Down-regulation of Cyclin A Expression Requires a Functional TGF-beta Receptor Complex
J. Biol. Chem., October 13, 1995; 270(41): 24237 - 24245.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation
Copyright © 1994 by the American Association of Cancer Research.